JP2020535180A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535180A5 JP2020535180A5 JP2020517814A JP2020517814A JP2020535180A5 JP 2020535180 A5 JP2020535180 A5 JP 2020535180A5 JP 2020517814 A JP2020517814 A JP 2020517814A JP 2020517814 A JP2020517814 A JP 2020517814A JP 2020535180 A5 JP2020535180 A5 JP 2020535180A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- compound
- cancer
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940126062 Compound A Drugs 0.000 claims 14
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 5
- 230000000771 oncological effect Effects 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 230000003463 hyperproliferative effect Effects 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 4
- 229960002621 pembrolizumab Drugs 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229950010773 pidilizumab Drugs 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17194196.6 | 2017-09-29 | ||
| EP17194196 | 2017-09-29 | ||
| PCT/EP2018/076494 WO2019063802A1 (en) | 2017-09-29 | 2018-09-28 | ANTICANCER ANTI-IGF POLY THERAPY, ANTI PD-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020535180A JP2020535180A (ja) | 2020-12-03 |
| JP2020535180A5 true JP2020535180A5 (enExample) | 2021-11-11 |
Family
ID=60009481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517814A Pending JP2020535180A (ja) | 2017-09-29 | 2018-09-28 | 抗ｉｇｆ、抗ｐｆ−１の抗がん組み合わせ治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200239559A1 (enExample) |
| EP (1) | EP3687573A1 (enExample) |
| JP (1) | JP2020535180A (enExample) |
| CN (1) | CN111148534A (enExample) |
| WO (1) | WO2019063802A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019021032A2 (pt) * | 2017-04-05 | 2020-05-05 | Boehringer Ingelheim Int | terapia combinada anticâncer |
| CA3148291A1 (en) * | 2019-09-11 | 2021-03-18 | Boehringer Ingelheim Io Canada, Inc. | Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies |
| CN112111575B (zh) * | 2020-09-22 | 2023-01-10 | 重庆医科大学附属第一医院 | 胰岛素样生长因子2在恶性肿瘤预后和治疗选择中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| PL2242773T3 (pl) | 2008-02-11 | 2017-11-30 | Cure Tech Ltd. | Przeciwciała monoklonalne do leczenia nowotworu |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| CN103396487A (zh) * | 2008-12-12 | 2013-11-20 | 贝林格尔.英格海姆国际有限公司 | 抗igf抗体 |
| US20130122005A1 (en) * | 2011-10-27 | 2013-05-16 | Paul Adam | Anticancer combination therapy |
| US20140255413A1 (en) * | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| HRP20192260T1 (hr) * | 2014-01-24 | 2020-03-06 | Boehringer Ingelheim International Gmbh | Liječenje raka uporabom antagonista receptora faktora rasta nalik inzulinu (igf) u kombinaciji s eksemestanom i everolimusom |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| MX389663B (es) | 2014-10-14 | 2025-03-20 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas. |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| US20170088609A1 (en) * | 2015-09-28 | 2017-03-30 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
| JP2019509282A (ja) * | 2016-02-29 | 2019-04-04 | ファウンデーション・メディシン・インコーポレイテッド | 癌の治療方法 |
-
2018
- 2018-09-28 US US16/649,763 patent/US20200239559A1/en not_active Abandoned
- 2018-09-28 EP EP18773782.0A patent/EP3687573A1/en not_active Withdrawn
- 2018-09-28 WO PCT/EP2018/076494 patent/WO2019063802A1/en not_active Ceased
- 2018-09-28 CN CN201880063798.0A patent/CN111148534A/zh active Pending
- 2018-09-28 JP JP2020517814A patent/JP2020535180A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| JP2013520442A5 (enExample) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2020521797A5 (enExample) | ||
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2019536806A5 (enExample) | ||
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| JP2017031160A5 (enExample) | ||
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| JP2015532292A5 (enExample) | ||
| JP2013529183A5 (enExample) | ||
| FI3845245T3 (fi) | Seerumin fosfaatin efektiivinen ja tehokas säätely optimaalista luunmuodostusta varten | |
| JP2016502504A5 (enExample) | ||
| JP2016519650A5 (enExample) | ||
| JP2015514110A5 (enExample) | ||
| HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
| FI3110440T3 (fi) | Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi | |
| RU2018123709A (ru) | Новые антитела для лечения онкологических заболеваний | |
| RU2017136709A (ru) | Комбинированное лечение немелкоклеточного рака легкого с выявленной мутацией в egfr | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2020522281A5 (enExample) | ||
| JP2019512472A5 (enExample) | ||
| PE20160994A1 (es) | Compuestos al receptor-3 del factor de crecimiento del fibroblasto (fgfr3) y metodos de tratamiento | |
| JP2018512402A5 (enExample) |